Former CEO says Biogen 'shot themselves in the foot' by deciding to charge $56,000 for its controversial Alzheimer's drug
, which concluded that Biogen set an"unjustifiably high price."
"If they priced it at $10,000, we wouldn't be having this discussion," he added."Everyone would be happily using it."Atthapon Raksthaput/ShutterstockWhile drugmakers often talk publicly about setting prices based on a drug's value to patients, Biogen's decision boiled down to maximizing profits, according to.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Alzheimer’s drug saga prompts journal to scrutinize whistle-blowersPublication requires complainants to disclose financial conflicts in the wake of controversy over Cassava Sciences’ experimental treatment simufilam.
Les mer »
National research teams seek Alzheimer's clinical trial participants for new studyRecently, a drug shown to modestly slow the early stages of Alzheimer's was approved by FDA. The drug continues to be studied in larger and longer trials.
Les mer »
This Biomarker Can Foreshadow Early Alzheimer's Years Before SymptomsA simple blood test could one day diagnose a rare inherited form of Alzheimer's disease, decades before symptoms of memory loss even appear.
Les mer »
Korea’s smart lens technology could detect Alzheimer’s at early stagesAlzheimer’s disease affects over 50 million people throughout the world. This new research may be able to detect it early.
Les mer »
HRT May Prevent Alzheimer's in High-Risk WomenHormone replacement therapy introduced early during the menopausal transition may protect against Alzheimer's dementia in women carrying the APOE4 gene, new research suggests.
Les mer »
Dementia: Brain check-up tool aims to cut risk at any ageYou are never too young to start improving your brain health, an Alzheimer's charity says.
Les mer »